Status:
COMPLETED
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver
Lead Sponsor:
Eli Lilly and Company
Conditions:
Liver Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.
Eligibility Criteria
Inclusion
- Diagnosis of cancer of the liver which is metastatic or locally recurrent and not amendable to curative therapy.
- Patient must have measurable disease
- Patient may have received prior arterial chemoembolization, completed 8 weeks prior to study enrollment, but no other previous chemotherapy
- Prior radiation is permitted, but must be completed at least 2 weeks prior to study enrollment.
- Prior central nervous system metastases are acceptable if the patient has received radiation ot the brain, is not on steroids, and does not have related symptoms.
Exclusion
- Patients who have had prior therapy with Pemetrexed.
- Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
- Patients who have received radiation to more than 25% of marrow
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT00191412
Start Date
January 1 2005
End Date
March 1 2006
Last Update
November 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Denver, Colorado, United States